Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy

Veterinary Journal

Volumn 193, Issue 1, 2012, Pages 264-267

  Kobayashi, Masato ^a   Sugisaki, Osamu ^a   Ishii, Noriko ^a   Yamada, Osamu ^a   Ito, Keita ^a   Kuroki, Shiori ^a   Sasaki, Yu ^a   Ono, Kenichiro ^a,b   Washizu, Tsukimi ^a   Bonkobara, Makoto ^a  

^a NIPPON VETERINARY AND LIFE SCIENCE UNIVERSITY   (Japan)

^b Japan Animal Referral Medical Center   (Japan)

Author keywords

C kit mutation; Dog; Imatinib; Intestinal mast cell tumor; Targeted therapy

Indexed keywords

COMPLEMENTARY DNA; IMATINIB; STEM CELL FACTOR RECEPTOR;

ABDOMINAL MASS; ANIMAL CELL; ARTICLE; ASPIRATION BIOPSY; CONTROLLED STUDY; DOG; DRUG RESPONSE; ECHOGRAPHY; EXON; FEMALE; GENE MUTATION; INTERNAL TANDEM DUPLICATION; INTESTINAL MAST CELL TUMOR; INTESTINE TUMOR; MELENA; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C KIT; PHYSICAL EXAMINATION; PROTEIN PHOSPHORYLATION; SPLEEN METASTASIS; TUMOR CELL; TUMOR REGRESSION; TUMOR VOLUME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; DOG DISEASES; DOGS; FEMALE; INTESTINAL NEOPLASMS; MASTOCYTOSIS, SYSTEMIC; PHOSPHORYLATION; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 84863778738     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2011.10.027     Document Type: Article

References (8)

1. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., Leversha M.A., Jeffrey P.D., Desantis D., Singer S., Brennan M.F., Maki R.G., DeMatteo R.P. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical Cancer Research 2005, 11:4182-4190.
2. Isotani M., Ishida N., Tominaga M., Tamura K., Yagihara H., Ochi S., Kato R., Kobayashi T., Fujita M., Fujino Y., Setoguchi A., Ono K., Washizu T., Bonkobara M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2008, 22:985-988.
3. Isotani M., Yamada O., Lachowicz J.L., Tamura K., Yagihara H., Fujino Y., Ono K., Washizu T., Bonkobara M. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours. British Journal of Haematology 2010, 148:144-153.
4. Letard S., Yang Y., Hanssens K., Palmérini F., Leventhal P.S., Guéry S., Moussy A., Kinet J.P., Hermine O., Dubreuil P. Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Molecular Cancer Research 2008, 6:1137-1145.
5. Peng B., Hayes M., Resta D., Racine-Poon A., Druker B.J., Talpaz M., Sawyers C.L., Rosamilia M., Ford J., Lloyd P., Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology 2004, 22:935-942.
6. Takahashi T., Kadosawa T., Nagase M., Matsunaga S., Mochizuki M., Nishimura R., Sasaki N. Visceral mast cell tumors in dogs: 10 Cases (1982-1997). Journal of the American Veterinary Medical Association 2000, 216:222-226.
7. Xiang Z., Kreisel F., Cain J., Colson A., Tomasson M.H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Molecular and Cellular Biology 2007, 27:267-282.
8. Yamada O., Kobayashi M., Sugisaki O., Ishii N., Ito K., Kuroki S., Sasaki Y., Isotani M., Ono K., Washizu T., Bonkobara M. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation. Veterinary Immunology and Immunopathology 2011, 142:101-106.